Monoclonal antibodies directed to the HER2 receptor
US5677171A · kind A · utility
422Cited by
8References
39Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 5, 1994 |
| Grant date | Oct 14, 1997 |
| Priority date | — |
| Expiry date | Aug 5, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monoclonal antibodies which bind to the extracellular domain of the HER2 receptor and inhibit growth of SK-BR-3 breast tumor cells, which overexpress HER2, are disclosed. The monoclonal antibodies can be used for in vitro assays for detecting a tumor characterized by amplified expression of HER2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.